SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 22: 110510.
  • 2
    Feldmann M, Maini RN. Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69: 128.
  • 3
    Reimold AM. TNFα as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 2002; 1: 37792.
  • 4
    Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 2004; 6 Suppl 2: S128.
  • 5
    Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004; 22: 3953.
  • 6
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 7
    Charles PJ, Smeenk RJ, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 238390.
  • 8
    De Rycke L, Kruithof E, van Damme N, Hoffman IE, van den Bossche N, van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48: 101523.
  • 9
    Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003; 30: 255762.
  • 10
    Bobbio-Pallavincini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: R26472.
  • 11
    Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-α. Ann Rheum Dis 2005; 64: 4037.
  • 12
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6: R53543.
  • 13
    Remicade [package insert]. Malvern (PA): Centocor Corporation, 2002.
  • 14
    Enbrel [package insert]. Seattle (WA): Immunex Corporation, 2003.
  • 15
    Kruithof E, van den Bosch F, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 20712.
  • 16
    Vermeire S, Noman M, van Assche G, Baert F, van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: a prospective study. Gastroenterology 2003; 125: 329.
  • 17
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 87685.
  • 18
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondyloarthropathy Study Group. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34: 121827.
  • 19
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 20
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 21
    Humbel RL. Detection of antinuclear antibodies by immunofluorescence. In: van VenrooijWJ, MainiRN, editors: Manual of biological markers of disease. Dordrecht (The Netherlands): Kluwer Academic publishers; 1993. p. 116.
  • 22
    Sanchez-Guerrero J, Lew RA, Fossel AH, Schur PH. Utility of anti-Sm, anti-RNP, anti–Ro/SS-A, and anti–La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum 1996; 39: 105561.
  • 23
    Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53: 42432.
  • 24
    Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 1998; 18: 5962.
  • 25
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1999; 130: 47886.
  • 26
    Baeten D, Kruithof E, van den Bosch F, Demetter P, van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti–tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 18695.
  • 27
    Cocca BA, Cline AM, Radic MZ. Blebs and apoptotic bodies are B cell autoantigens. J Immunol 2002; 169: 15966.
  • 28
    Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 177485.
  • 29
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005; 52: 6172.
  • 30
    Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 34.
  • 31
    Paul E, Carroll M. SAP-less chromatin triggers systemic lupus erythematosus. Nat Med 1999; 5: 6078.
  • 32
    Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002; 196: 13540.
  • 33
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Denis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 152633.
  • 34
    Szomolanyi-Tsuda E, Le QP, Garcea RL, Welsh RM. T-cell-independent immunoglobulin G responses in vivo are elicited by live-virus infection but not by immunization with viral proteins or virus-like particles. J Virol 1998; 72: 666570.
  • 35
    Richards HB, Satoh M, Jennette JC, Okano T, Kanwar YS, Reeves WH. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol 1999; 115: 54753.
  • 36
    Tran TT, Reich CF III, Alam M, Pisetsky DS. Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with CpG oligonucleotide as adjuvant. Clin Immunol 2003; 109: 27887.
  • 37
    Fields ML, Seo SJ, Nish SA, Tsai JH, Caton AJ, Erikson J. The regulation and activation potential of autoreactive B cells. Immunol Res 2003; 27: 21934.
  • 38
    Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003; 111: 150518.
  • 39
    Wellmann U, Letz M, Schneider A, Amann K, Winkler TH. An Ig μ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice. Int Immunol 2001; 13: 14619.
  • 40
    Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004; 104: 364754.
  • 41
    Werle E, Blazek M, Hiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992; 1: 36977.
  • 42
    Miltenburg AM, Roos A, Slegtenhorst L, Daha MR, Breeveld FC. IgA anti-dsDNA antibodies in SLE: occurrence, incidence and association with clinical and laboratory variables of disease activity. J Rheumatol 1993; 20: 538.
  • 43
    Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, et al. Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996; 25: 3529.
  • 44
    Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol 1999; 11: 35763.
  • 45
    Khanna D, McMahon M, Furst ED. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27: 30724.
  • 46
    Jonsdottir T, Forslid J, van Vollenhoven AM, Harju A, Brannemark SA, Klareskog L, et al. Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004; 63: 10758.